Key result
The High-STEACS diagnostic pathway using a novel high-sensitivity cardiac troponin I assay safely ruled out 30-day MI or cardiac death with a negative predictive value of 99.5%.
Why the study?
High-sensitivity cardiac troponin assays enable early risk stratification in suspected ACS, but the performance of a novel high-sensitivity cardiac troponin I assay in early rule out pathways required evaluation.
Do early rule-out pathways using low risk-stratification thresholds of high-sensitivity cardiac troponin I improve negative predictive value for myocardial infarction or cardiac death compared to the 99th centile threshold in patients with suspected acute coronary syndrome?
Cohort (n=1,920)
Do early rule-out pathways using low risk-stratification thresholds of high-sensitivity cardiac troponin I improve negative predictive value for myocardial infarction or cardiac death compared to the 99th centile threshold in patients with suspected acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Diagnostic pathways using low high-sensitivity cardiac troponin I concentrations for risk stratification safely rule out myocardial infarction and miss fewer events than those relying on the 99th centile threshold.
Background High-sensitivity cardiac troponin assays enable the early risk stratification of patients with suspected acute coronary syndrome to identify those at low risk of myocardial infarction or cardiac death. We evaluated the performance of a novel high-sensitivity cardiac troponin I assay in early rule out pathways. Methods In 1920 patients with suspected acute coronary syndrome, cardiac troponin was measured using the Siemens Atellica high-sensitivity cardiac troponin I assay (99th centile: 34 ng/L women, 53 ng/L men). We evaluated three pathways which use either low risk-stratification thresholds of cardiac troponin ( High-S ensitivity T roponin in the E valuation of patients with A cute C oronary S yndrome (High-STEACS) and the European Society of Cardiology (ESC) 1 hour pathway) or the 99th centile diagnostic threshold (ESC 3 hour pathway) to rule out myocardial infarction. Results The primary outcome of myocardial infarction or cardiac death at 30 days occurred in 14.4% (277/1920). The High-STEACS pathway ruled out 63% of patients (1218/1920), with five missed events for a negative predictive value (NPV) of 99.5% (95% CI (CI) 99.1% to 99.8%). Similar performance was observed for the ESC 1 hour pathway with an NPV of 99.0% (97.6% to 99.8%). In contrast, the ESC 3 hour pathway ruled out 65% of patients (1248/1920), but missed 25 events for an NPV of 98.0% (97.1% to 98.7%). Conclusions A novel high-sensitivity cardiac troponin I assay can safely identify patients at low risk of myocardial infarction or cardiac death. Diagnostic pathways that use low cardiac troponin concentrations for risk stratification miss fewer events than those that rely on the 99th centile to rule out myocardial infarction. Trial registration NCT1852123.
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2018) conducted a cohort in Suspected acute coronary syndrome (n=1,920). High-STEACS and ESC 1-hour diagnostic pathways vs. ESC 3-hour diagnostic pathway was evaluated on Myocardial infarction or cardiac death at 30 days (95% CI 99.1 to 99.8). The High-STEACS diagnostic pathway using a novel high-sensitivity cardiac troponin I assay safely ruled out 30-day MI or cardiac death with a negative predictive value of 99.5%.
Synapse has enriched 10 related papers. Consider them for comparative context: